Journal of pediatric endocrinology & metabolism : JPEM · 2026
Sterile abscesses during GnRH agonist therapy for central precocious puberty: a case series and literature review.
СтатьяКлинический случайОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sarli Walter Maria, Tartarini Carlotta, Chiti Nicolò, Varriale Gaia, Ricci Silvia, Stagi Stefano
Аннотация
OBJECTIVES: Long-acting gonadotropin-releasing hormone agonists (GnRHa) are standard therapy for central precocious puberty (CPP). Depot formulations (triptorelin, leuprolide) ensure sustained release via biodegradable matrices. Rare sterile injection-site abscesses may impair drug absorption and efficacy, and evidence on management is limited.
CASES PRESENTATION: Two patients (0.68 %) out of the 290 treated at our center with depot GnRHa between 2023 and 2025 developed recurrent culture-negative abscesses. They had normal immune workup and no IgE-mediated hypersensitivity or mastocytosis. Lesions caused pain, transient inflammation, and reduced efficacy. In one case, topical hydrocortisone butyrate 0.1 % for 5 days post-injection resolved abscesses and restored efficacy.
CONCLUSIONS: Sterile abscesses are a rare but relevant complication of GnRHa therapy. Early recognition and exclusion of infection/allergy are key. Our experience with a patient who showed a good response to topical corticosteroids may be relevant in offering a conservative therapeutic option to treat the abscess lesion without discontinuing GnRHa therapy.
CASES PRESENTATION: Two patients (0.68 %) out of the 290 treated at our center with depot GnRHa between 2023 and 2025 developed recurrent culture-negative abscesses. They had normal immune workup and no IgE-mediated hypersensitivity or mastocytosis. Lesions caused pain, transient inflammation, and reduced efficacy. In one case, topical hydrocortisone butyrate 0.1 % for 5 days post-injection resolved abscesses and restored efficacy.
CONCLUSIONS: Sterile abscesses are a rare but relevant complication of GnRHa therapy. Early recognition and exclusion of infection/allergy are key. Our experience with a patient who showed a good response to topical corticosteroids may be relevant in offering a conservative therapeutic option to treat the abscess lesion without discontinuing GnRHa therapy.